News
ARDX
6.54
+3.57%
0.23
Weekly Report: what happened at ARDX last week (0415-0419)?
Weekly Report · 4d ago
Ardelyx Is Maintained at Outperform by Wedbush
Dow Jones · 04/17 17:03
Ardelyx Price Target Raised to $14.00/Share From $13.00 by Wedbush
Dow Jones · 04/17 17:03
Wedbush Maintains Outperform on Ardelyx, Raises Price Target to $14
Benzinga · 04/17 16:54
Weekly Report: what happened at ARDX last week (0408-0412)?
Weekly Report · 04/15 10:24
Weekly Report: what happened at ARDX last week (0401-0405)?
Weekly Report · 04/08 10:27
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Byrna Technologies shares jumped 7.1% to $14.74 on Friday. The company reported better-than-expected first-quarter revenue and announced a CFO transition. MediaCo Holding Inc. Shares jumped 141.7% in today's mid-day session.
Benzinga · 04/05 17:06
Ardelyx Price Target Announced at $14.00/Share by Leerink Partners
Dow Jones · 04/05 12:07
Ardelyx Initiated at Outperform by Leerink Partners
Dow Jones · 04/05 12:07
A Closer Look at 6 Analyst Recommendations For Ardelyx
Ardelyx Inc is a biotechnology company focused on the discovery, development and commercialization of medicines. The company has an average 12-month price target of $14.0. The average price target is an increase of 33.33% from the previous average of $10.50. ArdelyX has 6 analysts' ratings ranging from bullish to bearish for the company.
Benzinga · 04/05 12:00
Leerink Partners Initiates Coverage On Ardelyx with Outperform Rating, Announces Price Target of $14
Benzinga · 04/05 11:57
ARDELYX INC <ARDX.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $14
Reuters · 04/05 11:43
Weekly Report: what happened at ARDX last week (0325-0329)?
Weekly Report · 04/01 10:26
Ardelyx Enters Oversold Territory (ARDX)
NASDAQ · 03/28 20:23
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. Granted stock options to Michael Kelliher in connection with his employment. The company's board of directors also granted 14 new non-executive employees options to purchase shares of the company's common stock. Each stock option has an exercise price equal to $7.70 per share.
Barchart · 03/28 15:05
*Ardelyx: Kelliher Served as Group Vice Pres, M&A and Business Development, at Horizon Therapeutics >ARDX
Dow Jones · 03/25 12:01
*Ardelyx Appoints Mike Kelliher, as Executive Vice Pres, Corporate Development and Strategy
Dow Jones · 03/25 12:01
Weekly Report: what happened at ARDX last week (0318-0322)?
Weekly Report · 03/25 10:28
Weekly Report: what happened at ARDX last week (0311-0315)?
Weekly Report · 03/18 10:27
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Seeking Alpha · 03/13 22:00
More
Webull provides a variety of real-time ARDX stock news. You can receive the latest news about Ardelyx through multiple platforms. This information may help you make smarter investment decisions.
About ARDX
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.